Boryung said on the 30th that it signed a contract development and manufacturing organization (CDMO) agreement with Zuellig Pharma, a pharmaceutical company headquartered in Singapore, to supply the original cytotoxic anticancer drug "Alimta (ingredient name pemetrexed)" in Southeast Asia.
Under the agreement, Boryung will supply Alimta injections to seven Southeast Asian countries—Philippines, Thailand, Malaysia, Indonesia, Brunei, Cambodia, and Myanmar—from 2027. The contract period is five years, and it will be produced at Boryung's Yesan Campus. The contract amount was not disclosed.
The company said, "This collaboration with Zuellig Pharma is a case that shows Boryung is expanding its global CDMO business, especially in the cytotoxic anticancer CDMO sector," and noted, "Through this collaboration, we expect profit growth to begin in earnest from the time each country's approval procedures are completed."
Boryung said its strategic goal is to go beyond simple production supply to achieve qualitative improvement in its profit structure and globalize its business fundamentals. Starting with a cytotoxic anticancer drug supply contract with Lotus in Taiwan last year, the company signed a supply contract for Zyprexa with Cheplapharm in Jul., and for Alimta with Zuellig Pharma this time.
Kim Sung-jin, Boryung's chief strategy officer (CSO), said, "Boryung will establish itself as a stable and reliable supplier in the field of cytotoxic anticancer drugs based on global-level production infrastructure, quality, and R&D capabilities."